In relation to these broad drivers for CVD, GLP-1 can mitigate metabolic stressors by curbing excess nutrient intake through the promotion of satiety, weight loss, and reducing hyperglycemia and lipid levels [3,4,5]
*Compounded drugs are permitted to be prescribed under federal law but are not FDA-approved and do not undergo FDA review for safety, effectiveness, or quality.
In preclinical models of glaucoma, neuroprotection appears to be strongly linked to the anti-inflammatory properties of GLP-1RAs
Can I switch medications if needed
On April 30, 2026, the FDA formally proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list (Federal Register docket 2026-08552), citing no current clinical need for outsourcing facilities to compound these drugs from bulk drug substances